NCT00005849View on ClinicalTrials.gov

Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 30, 2000

Primary Completion Date

September 30, 2002

Study Completion Date

November 30, 2003

Conditions
Lung Cancer
Interventions
DRUG

bryostatin 1

DRUG

paclitaxel

Trial Locations (10)

46617

Michiana Hematology/Oncology P.C., South Bend

60068

Lutheran General Cancer Care Center, Park Ridge

60201

Evanston Northwestern Health Care, Evanston

60612

University of Illinois at Chicago, Chicago

60637

University of Chicago Cancer Research Center, Chicago

60640

Louis A. Weiss Memorial Hospital, Chicago

61602

Oncology/Hematology Associates of Central Illinois, P.C., Peoria

62526

Decatur Memorial Hospital Cancer Care Institute, Decatur

62701

Central Illinois Hematology Oncology Center, Springfield

46885-5099

Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Chicago

OTHER

NCT00005849 - Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter